Cross-Sector entity
Baldwin is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. market-trends accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. The tracked stories average 3 original sources each. MDxHealth appears in 2 tracked Cross-Sector stories from February 27, 2026.
2 verified stories tracked
Last mentioned: Feb 27, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Baldwin is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. market-trends accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. The tracked stories average 3 original sources each. MDxHealth appears in 2 tracked Cross-Sector stories from February 27, 2026.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering MDxHealth. Shared-story counts are live from our verified record — not editorial picks.
NDA Submission
Planned submission of paltusotine New Drug Application to the FDA.
Phase 3 Initiation
Anticipated start of Phase 3 trials for atumelnant in CAH and Cushing's disease.
Earnings Call
Management confirms commercial readiness and pipeline acceleration.
PATHFNDR-2 Success
Completion of Phase 3 trial for paltusotine in acromegaly with positive results.
Crinetics Pharmaceuticals reported strong Q4 2025 results, highlighting the successful completion of Phase 3 trials for paltusotine and preparations for a 2026 New Drug Application (NDA). The company is positioning itself for a major commercial pivot in endocrine disorders, supported by a robust balance sheet and positive data for its second lead candidate, atumelnant.
The Q4 2025 earnings reports from Crinetics, MDxHealth, and Baldwin highlight a pivotal shift toward precision diagnostics and specialized endocrine therapies. These results underscore a robust recovery in diagnostic volumes and a maturing pipeline for rare disease treatments entering commercialization phases.
Source: seekingalpha.com · flipboard.com
